Serum miR-181а and miR-25 Levels in Patients with Breast Cancer or Benign Breast Disease.

Publisher: Pleiades Publishing Country of Publication: United States NLM ID: 101126895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1608-3091 (Electronic) Linking ISSN: 16076729 NLM ISO Abbreviation: Dokl Biochem Biophys Subsets: MEDLINE

Publication: New York, NY : Pleiades Publishing
Original Publication: Moscow, Russia : [Dordrecht] : International Academic Pub. Co. "Nauka/Interperiodica" ; Distributed worldwide by Kluwer Academic/Plenum Publishers, c2001-

Breast Neoplasms*/genetics ; Breast Neoplasms*/pathology ; Triple Negative Breast Neoplasms*/genetics ; Triple Negative Breast Neoplasms*/pathology ; MicroRNAs*/genetics ; MicroRNAs*/metabolism; Humans ; Female ; Biomarkers, Tumor/metabolism

Circulating miR-181а and miR-25, which reflect regulation of the expression of carcinogenesis-related genes, were assayed in patients with invasive carcinoma of no specific type (ICNT) or benign breast diseases (BBDs) and in subjects without pathologies of the mammary gland (controls). miR-181а expression level proved to be higher compared to control in patients with fibroadenoma and adenosis with low, but not high, risk of malignant transformation, as well as in patients with luminal HER2-negative type B (Lum B HER2-), HER2-positive type (HER2+), and triple-negative breast cancer (TNBC) than in the controls and luminal-type (Lum A) breast cancer. MiR-25 expression level prevailed in patients with Lum B HER2- compared to control, Lum A, and TNBC patients compared to Lum A. Thus, miR-181а and miR-25 expression levels may be risk indicators of malignant transformation in some patients with BBD, whereas in patients with ICNT, these levels reflect pathological processes of different directions within the tumor.
(© 2023. Pleiades Publishing, Ltd.)

Zhai, Z., Mu, T., Zhao, L., Li, Y., et al., Mir-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway, Bioengineered, 2022, vol. 13, no. 1, pp. 83–95. (PMID: 10.1080/21655979.2021.200697434951340)
Yang, C., Tabatabaei, S.N., Ruan, X., et al., The dual regulatory role of mir-181a in breast cancer, Cell Physiol. Biochem., 2017, vol. 44, no. 3, pp. 843–856. (PMID: 10.1159/00048535129176320)
Mahmoudian, M., Razmara, E., Mahmud, Hussen B., et al., Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues, J. Clin. Lab. Anal., 2021, vol. 35, no. 11, p. e24010. (PMID: 10.1002/jcla.24010345283148605139)
Bisso, A., Faleschini, M., Zampa, F., et al., Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer, Cell Cycle, 2013, vol. 12, no. 11, pp. 1679–1687. (PMID: 10.4161/cc.24757236567903713126)
Li, Y., Kuscu, C., Banach, A., et al., MiR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14, Cancer Res., 2015, vol. 75, no. 13, pp. 2674–2685. (PMID: 10.1158/0008-5472.CAN-14-2875259773384489986)
Farazi, T.A., Ten Hoeve, J.J., Brown, M., et al., Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets, Genome Biol., 2014, vol. 15, no. 1, p. R9. (PMID: 10.1186/gb-2014-15-1-r9243983244053773)
Wang, L.J., Chiou, J.T., Lee, Y.C., et al., Docetaxel-triggered SIDT2/NOX4/JNK/HuR signaling axis is associated with TNF-alpha-mediated apoptosis of cancer cells, Biochem. Pharmacol., 2022, vol. 195, p. 114865. (PMID: 10.1016/j.bcp.2021.11486534863979)
Chen, H., Pan, H., Qian, Y., et al., MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2, Mol. Cancer, 2018, vol. 17, no. 1, p. 4. (PMID: 10.1186/s12943-017-0754-0293106805759260)
Yao, J., Li, G., Liu, M., et al., lncMICAL21 sponges miR25 to regulate DKK3 expression and inhibits activation of the Wnt/beta-catenin signaling pathway in breast cancer, Int. J. Mol. Med., 2022, vol. 49, no. 2.
Hu, Z.B., Dong, J., Wang, L.E., et al., Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls, Carcinogenesis, 2012, vol. 33, no. 4, pp. 828–834. (PMID: 10.1093/carcin/bgs03022298638)
Malherbe, K., Khan, M., and Fatima, S., Fibrocystic Breast Disease, Treasure Island, FL: StatPearls Publishing, 2022.
Breast Tumours, WHO Classification of Tumours Editorial Board, Eds., Lyon: International Agency for Besearch on Cancer; 2019, 5th ed.
Erber, R., Angeloni, M., Stohr, R., et al., Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test—comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting, Int. J. Mol. Sci., 2022, vol. 23, no. 15.
Zendehdel, M., Niakan, B., Keshtkar, A., et al., Subtypes of benign breast disease as a risk factor for breast cancer: a systematic review and meta-analysis protocol, Iran J. Med. Sci., 2018, vol. 43, no. 1, pp. 1–8. (PMID: 293987465775989)
Holm, K., Hegardt, C., Staaf, J., Ringner, M., et al., Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns, Breast Cancer Res., 2010, vol. 12, no. 3, p. R36. (PMID: 10.1186/bcr2590205658642917031)
Humphries, B., Wang, Z., and Yang, C., MicroRNA regulation of epigenetic modifiers in breast cancer, Cancers (Basel), 2019, vol. 11, no. 7.
Stagni, V., Manni, I., Oropallo, V., et al., ATM kinase sustains HER2 tumorigenicity in breast cancer, Nat. Commun., 2015, vol. 6, p. 6886. (PMID: 10.1038/ncomms788625881002)
Taylor, M.A., Sossey-Alaoui, K., Thompson, C.L., et al., TGF-beta upregulates miR-181a expression to promote breast cancer metastasis, J. Clin. Invest., 2013, vol. 123, no. 1, pp. 150–163. (PMID: 10.1172/JCI6494623241956)
Vishnubalaji, R. and Alajez, N.M., Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-beta signaling, Sci. Rep., 2021, vol. 11, no. 1, p. 15410. (PMID: 10.1038/s41598-021-94514-9343263728322425)
Tanic, M., Yanowski, K., Gomez-Lopez, G., et al., MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors, Int. J. Cancer, 2015, vol. 136, no. 3, pp. 593–602. (PMID: 10.1002/ijc.2902124917463)

Keywords: benign breast disease; biomarkers; breast cancer; miR-181а; miR-25

0 (MicroRNAs)
0 (Biomarkers, Tumor)
0 (MIRN25 microRNA, human)

Date Created: 20231213 Date Completed: 20231216 Latest Revision: 20231216

20250114

10.1134/S1607672923700436

38093131